Fig. 6: mTORC1 activation drives CpG-induced macrophage activation syndrome.
From: mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome
a Phospho-S6 staining (n = 8 per group) and (b) phospho-4EBP1 staining (n = 5 per group) in bone marrow Ly6Chi monocytes, (c) flow cytometry quantification of peripheral blood and bone marrow Ly6Chi monocytes (n = 8 per group), (d) hematologic parameters (n = 11 per group) and ferritin levels (PBS, n = 5; CpG + Vehicle, n = 8; CpG + Rapamycin, n = 8), (e) absolute bone marrow cell count (n = 8 per group), (f) representative depiction and quantification of spleen size (n = 8 per group), (g) liver size (n = 8 per group), and (h) plasma cytokine levels (PBS, n = 3; CpG + Vehicle, n = 8; CpG + Rapamycin, n = 8), in PBS-treated or CpG DNA-treated C57BL/6 mice (50 µg every 2 days x 5 doses) given daily rapamycin or vehicle control. Data in (a, b) were normalized to the mean fluorescence intensity (MFI) of the PBS group. Mice were 8 weeks old and data from all panels were pooled from 2 to 3 independent experiments. Statistical analyses (all two-sided): Mann–Whitney U test (all panels). Median and error bars representing interquartile range are displayed in (a–h). Source data are provided as a Source Data file.
